Analysis of the Effect of Capecitabine Combined with Synchronized Chemoradiotherapy in the Treatment of Middle and Advanced Esophageal Cancer
Objective To explore the value of capecitabine combined with synchronized chemoradiotherapy in the treatment of middle and advanced esophageal cancer.Methods A total of 82 patients with middle and advanced esophageal cancer admitted to Guangxi Hezhou People's Hospital from January 2019 to December 2022 were selected as the study subjects.They were divided into study group(41 cases)and comparison group(41 cases)by random number table method.The comparison group was given concurrent chemoradiotherapy,and capecitabine was added to the study group on the basis of the comparison group.The clinical efficacy,immune function and inflammatory fac-tors were compared between the two groups.Results The total clinical effective rate of the study group was higher than that of the comparison group(82.93%vs 60.98%),and the difference was statistically significant(χ2=4.895,P<0.05).Before treatment,there was no significant difference in immune function between the two groups(P>0.05).Af-ter treatment,the immune function of the study group was better than that of the comparison group,and the differ-ence was statistically significant(P<0.05).Before treatment,there was no significant difference in inflammatory fac-tors between the two groups(P>0.05).After treatment,the level of inflammatory factors in the study group was lower than that in the comparison group,and the difference was statistically significant(P<0.05).Conclusion Adopting capecitabine combined with synchronized chemoradiotherapy treatment regimen in the treatment of middle and ad-vanced esophageal cancer can promote the improvement of clinical efficacy,improve the immune function and allevi-ate the inflammatory response.
Middle and advanced esophageal cancerCapecitabineSynchronized chemoradiotherapy
NETL
NSTL
万方数据
